Evidence map›Paper›PMID 25214783›Full record

ArticleInternational journal of nanomedicine2014

Preparation and therapeutic evaluation of (188)Re-thermogelling emulsion in rat model of hepatocellular carcinoma.

Ying-Hsia Shih, Xi-Zhang Lin, Chung-Hsin Yeh, Cheng-Liang Peng, Ming-Jium Shieh, Wuu-Jyh Lin, Tsai-Yueh Luo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ying-Hsia ShihIsotope Application Division, Institute of Nuclear Energy Research, Longtan, Taiwan ; Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.
Xi-Zhang LinDepartment of Internal Medicine, National Cheng Kung University, Tainan, Taiwan.
Chung-Hsin YehIsotope Application Division, Institute of Nuclear Energy Research, Longtan, Taiwan.
Cheng-Liang PengIsotope Application Division, Institute of Nuclear Energy Research, Longtan, Taiwan ; Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.
Ming-Jium ShiehInstitute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan ; Department of Oncology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
Wuu-Jyh LinIsotope Application Division, Institute of Nuclear Energy Research, Longtan, Taiwan.
Tsai-Yueh LuoIsotope Application Division, Institute of Nuclear Energy Research, Longtan, Taiwan ; Institute of Radiological Science, Central Taiwan University of Science and Technology, Taichung, Taiwan.
Institute of Nuclear Energy Research · TWNational Taiwan University · TWNational Cheng Kung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiolabeled Lipiodol(®) (Guerbet, Villepinte, France) is routinely used in hepatoma therapy. The temperature-sensitive hydrogel polyethylene glycol-b-poly-DL-lactic acid-co-glycolic acid-b-polyethylene glycol triblock copolymer is used as an embolic agent and sustained drug release system. This study attempted to combine the polyethylene glycol-b-poly-DL-lactic acid-co-glycolic acid-b-polyethylene glycol hydrogel and radio-labeled Lipiodol to form a new radio-thermogelling emulsion, rhenium-188-N,N'-1,2-ethanediylbis-L-cysteine diethyl-ester dihydrochloride-Lipiodol/hydrogel ((188)Re-ELH). The therapeutic potential of (188)Re-ELH was evaluated in a rodent hepatoma model. Rhenium-188 chelated with N,N'-1,2-ethanediylbis-L-cysteine diethyl-ester dihydrochloride was extracted with Lipiodol to obtain rhenium-188-N,N'-1,2-ethanediylbis-L-cysteine diethyl-ester dihydrochloride-Lipiodol ((188)Re-EL), which was blended with the hydrogel in equal volumes to develop (188)Re-ELH. The (188)Re-ELH phase stability was evaluated at different temperatures. Biodistribution patterns and micro-single-photon emission computed tomography/computed tomography images in Sprague Dawley rats implanted with the rat hepatoma cell line N1-S1 were observed after in situ tumoral injection of ~3.7 MBq (188)Re-ELH. The therapeutic potential of (188)Re-EL (48.58±3.86 MBq/0.1 mL, n=12) was evaluated in a 2-month survival study using the same animal model. The therapeutic effects of (188)Re-ELH (25.52±4.64 MBq/0.1 mL, n=12) were evaluated and compared with those of (188)Re-EL. The responses were assessed by changes in tumor size and survival rates. The (188)Re-ELH emulsion was stable in the gel form at 25°C-35°C for >52 hours. Biodistribution data and micro-single-photon emission computed tomography/computed tomography images of the (188)Re-ELH group indicated that most activity was selectively observed in hepatomas. Long-term (188)Re-ELH studies have demonstrated protracted reductions in tumor volumes and positive effects on the survival rates (75%) of N1-S1 hepatoma-bearing rats. Conversely, the 2-month survival rate was 13% in the control sham group. Therapeutic responses differed significantly between the two groups (P<0.005). Thus, the hydrogel enhanced the injection stability of (188)Re-EL in an animal hepatoma model. Given the synergistic results, direct (188)Re-ELH intratumoral injection is a potential therapeutic alternative for hepatoma treatment.

Indexed as

AnimalsCarcinoma, HepatocellularDrug CombinationsEmulsionsHydrogelsIodized OilLiver Neoplasms, ExperimentalMaleOrganometallic CompoundsPolyethylene GlycolsPolyglactin 910RadioisotopesRatsRats, Sprague-DawleyRheniumSurvival AnalysisDrug CombinationsEmulsionsHydrogelsIodized OilOrganometallic Compoundspolyethylene glycol-poly(lactic-co-glycolic acid)-polyethylene glycolPolyethylene GlycolsPolyglactin 910RadioisotopesRheniumrhenium-188 ethyl cysteinate dimer lipiodol188Re-ECD-Lipiodolhepatomahydrogelthermogelling emulsion

Identifiers

PMID25214783
PMCPMC4159399
OpenAlexW2070844677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.